is tirzepatide or retatrutide better vs. Tirzepatide: The Next-Gen GLP-1 Showdown Retatrutide vs Tirzepatide (2026): Differences

CagriSema is a fixed-dose combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist), and is currently (as of March 27, 2025) an experimental obesity drug developed by Novo Nordisk

Compounded tirzepatide allows personalized dosing, multiple delivery formats (injection/oral), and flat pricing starting at $289/mo, making consistent treatment more accessible

By mimicking the action of the GLP-1 hormone, semaglutide helps to reduce appetite and increase feelings of fullness and satiety after meals

Badania dowodz, e oprcz cukrzycy i otyoci, leki te w przyszoci maj ogromny potencja w leczeniu lub zapobieganiu innych schorze